Abstract:Research demonstrates that the neural mechanisms underlying synaptic plasticity and learning and memory involve mobilization of AMPA-type neurotransmitter receptors at glutamatergic synaptic contacts, and that these mechanisms are targeted during neurodegenerative disease. Strengthening neural transmission occurs with insertion of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) into synapses while weakening results from receptor withdrawal. A key player in the trafficking of AMPARs during plasticity and learning is the brain-derived neurotrophic factor (BDNF) signaling system. BDNF is a neurotrophic factor that supports neuronal growth and is required for learning and memory. Significantly, a primary feature of many neurodegenerative diseases is a reduction in BDNF protein as well as disrupted neuronal surface expression of synaptic AMPARs. The resulting weakening of synaptic contacts leads to synapse loss and neuronal degeneration that underlies the cognitive impairment and dementia observed in patients with progressive neurodegenerative disease such as Alzheimer's. In the face of these data, one therapeutic approach is to increase BDNF bioavailability in brain. While this has been met with significant challenges, the results of the research have been promising. In spite of this, there are currently no clinical trials to test many of these findings on patients. Here, research showing that BDNF drives AMPARs to synapses, AMPAR trafficking is essential for synaptic plasticity and learning, and that neurodegenerative disease results in a significant decline in BDNF will be reviewed. The aim is to draw attention to the need for increasing patient-directed clinical studies to test the possible benefits of increasing levels of neurotrophins, specifically BDNF, to treat brain disorders. Much is known about the cellular mechanisms that underlie learning and memory in brain. It can be concluded that signaling by neurotrophins like BDNF and AMPA-type glutamate receptor synaptic trafficking are fundamental to these processes. Data from animal models and patients reveal that these mechanisms are adversely targeted during neurodegenerative disease and results in memory loss and cognitive decline. A brief summary of our understanding of these mechanisms indicates that it is time to apply this knowledge base directly to development of therapeutic treatments that enhance neurotrophins for brain disorders in patient populations.

Netrin-1 signaling pathway mechanisms in neurodegenerative diseases

Insights from the neural guidance factor Netrin-1 into neurodegeneration and other diseases

Netrin-1 receptor UNC5C cleavage by active -secretase enhances neurodegeneration, promoting Alzheimer's disease pathologies

The neuroimmune guidance cue netrin-1: a new therapeutic target in cardiovascular disease.

Protease Regulation: the Yin and Yang of Neural Development and Disease

Neuroprotection of netrin-1 on neurological recovery via Wnt/β-catenin signaling pathway after spinal cord injury.

Neuregulins in Neurodegenerative Diseases

Netrin-1 overexpression improves neurobehavioral outcomes and reduces infarct size via inhibition of the notch1 pathway following experimental stroke.

Neuron-derived Netrin-1 deficiency aggravates spinal cord injury through activating the NF-κB signaling pathway

Netrin-1 receptor UNC5C cleavage by active δ-secretase enhances neurodegeneration, promoting Alzheimer’s disease pathologies

lncRNA NEAT1: key player in neurodegenerative diseases

Regulation of AMPAR trafficking in synaptic plasticity by BDNF and the impact of neurodegenerative disease

Research progress of the netrins and their receptors in cancer

Potential Roles of Telomeres and Telomerase in Neurodegenerative Diseases.

Development of neurotrophic molecules for treatment of neurodegeneration

Netrin‐1 protects blood–brain barrier (BBB) integrity after cerebral ischemia‐reperfusion by activating the Kruppel‐like factor 2 (KLF2)/occludin pathway

Functions and the Related Signaling Pathways of the Neurotrophic Factor Neuritin

Netrin-1 controls inflammation in response to ischemic stroke through altering microglia phenotype.

Netrin-1 Attenuates Brain Injury after Middle Cerebral Artery Occlusion Via Downregulation of Astrocyte Activation in Mice

Netrin-1 rescues neuron loss by attenuating secondary apoptosis in ipsilateral thalamic nucleus following focal cerebral infarction in hypertensive rats.

Netrin induces down-regulation of its receptor, Deleted in Colorectal Cancer, through the ubiquitin-proteasome pathway in the embryonic cortical neuron.